|
|
|
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
|
Delaware
|
|
11-3131700
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
|
AMED
|
|
The NASDAQ Global Select Market
|
|
|
|
|
|
|
|
Large accelerated filer
|
|
☒
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
|||
Non-accelerated filer
|
|
☐
|
|
Smaller reporting company
|
|
☐
|
|
|
|
|
|||
Emerging growth company
|
|
☐
|
|
|
|
|
|
|
|
|
;;;
|
|
|
PART I.
|
|
|
ITEM 1.
|
|
|
|
||
|
||
|
||
|
||
ITEM 2.
|
||
ITEM 3
|
||
ITEM 4.
|
||
|
|
|
|
||
ITEM 1.
|
||
ITEM 1A.
|
||
ITEM 2.
|
||
ITEM 3.
|
||
ITEM 4.
|
||
ITEM 5.
|
||
ITEM 6.
|
||
|
September 30, 2019
(unaudited) |
|
December 31, 2018
|
||||
ASSETS
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
20,757
|
|
|
$
|
20,229
|
|
Patient accounts receivable
|
254,703
|
|
|
188,972
|
|
||
Prepaid expenses
|
10,601
|
|
|
7,568
|
|
||
Other current assets
|
13,458
|
|
|
7,349
|
|
||
Total current assets
|
299,519
|
|
|
224,118
|
|
||
Property and equipment, net of accumulated depreciation of $101,446 and $95,472
|
29,969
|
|
|
29,449
|
|
||
Operating lease right of use assets
|
84,124
|
|
|
—
|
|
||
Goodwill
|
660,472
|
|
|
329,480
|
|
||
Intangible assets, net of accumulated amortization of $36,799 and $33,050
|
66,468
|
|
|
44,132
|
|
||
Deferred income taxes
|
17,568
|
|
|
35,794
|
|
||
Other assets
|
54,260
|
|
|
54,145
|
|
||
Total assets
|
$
|
1,212,380
|
|
|
$
|
717,118
|
|
LIABILITIES AND EQUITY
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
35,901
|
|
|
$
|
28,531
|
|
Payroll and employee benefits
|
115,899
|
|
|
92,858
|
|
||
Accrued expenses
|
127,111
|
|
|
99,475
|
|
||
Current portion of long-term obligations
|
8,959
|
|
|
1,612
|
|
||
Current portion of operating lease liabilities
|
26,783
|
|
|
—
|
|
||
Total current liabilities
|
314,653
|
|
|
222,476
|
|
||
Long-term obligations, less current portion
|
231,641
|
|
|
5,775
|
|
||
Operating lease liabilities, less current portion
|
56,619
|
|
|
—
|
|
||
Other long-term obligations
|
6,002
|
|
|
6,234
|
|
||
Total liabilities
|
608,915
|
|
|
234,485
|
|
||
Commitments and Contingencies—Note 6
|
|
|
|
||||
Equity:
|
|
|
|
||||
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding
|
—
|
|
|
—
|
|
||
Common stock, $0.001 par value, 60,000,000 shares authorized; 36,599,273 and 36,252,280 shares issued; and 32,246,575 and 31,973,505 shares outstanding
|
37
|
|
|
36
|
|
||
Additional paid-in capital
|
634,854
|
|
|
603,666
|
|
||
Treasury stock, at cost 4,352,698 and 4,278,775 shares of common stock
|
(251,070
|
)
|
|
(241,685
|
)
|
||
Accumulated other comprehensive income
|
15
|
|
|
15
|
|
||
Retained earnings
|
218,728
|
|
|
119,550
|
|
||
Total Amedisys, Inc. stockholders’ equity
|
602,564
|
|
|
481,582
|
|
||
Noncontrolling interests
|
901
|
|
|
1,051
|
|
||
Total equity
|
603,465
|
|
|
482,633
|
|
||
Total liabilities and equity
|
$
|
1,212,380
|
|
|
$
|
717,118
|
|
|
For the Three-Month
Periods Ended September 30 |
|
For the Nine-Month
Periods Ended September 30 |
||||||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Net service revenue
|
$
|
494,631
|
|
|
$
|
417,335
|
|
|
$
|
1,454,955
|
|
|
$
|
1,228,200
|
|
Cost of service, excluding depreciation and amortization
|
288,708
|
|
|
249,739
|
|
|
854,734
|
|
|
730,612
|
|
||||
General and administrative expenses:
|
|
|
|
|
|
|
|
||||||||
Salaries and benefits
|
99,941
|
|
|
79,367
|
|
|
293,127
|
|
|
232,213
|
|
||||
Non-cash compensation
|
6,298
|
|
|
4,842
|
|
|
18,451
|
|
|
12,653
|
|
||||
Other
|
48,474
|
|
|
40,335
|
|
|
140,284
|
|
|
124,119
|
|
||||
Depreciation and amortization
|
4,366
|
|
|
3,164
|
|
|
12,440
|
|
|
9,882
|
|
||||
Operating expenses
|
447,787
|
|
|
377,447
|
|
|
1,319,036
|
|
|
1,109,479
|
|
||||
Operating income
|
46,844
|
|
|
39,888
|
|
|
135,919
|
|
|
118,721
|
|
||||
Other income (expense):
|
|
|
|
|
|
|
|
||||||||
Interest income
|
15
|
|
|
29
|
|
|
59
|
|
|
263
|
|
||||
Interest expense
|
(3,778
|
)
|
|
(1,991
|
)
|
|
(11,459
|
)
|
|
(5,834
|
)
|
||||
Equity in (losses) earnings from equity method investments
|
(812
|
)
|
|
1,625
|
|
|
4,120
|
|
|
6,461
|
|
||||
Miscellaneous, net
|
1,975
|
|
|
1,822
|
|
|
2,404
|
|
|
2,782
|
|
||||
Total other (expense) income, net
|
(2,600
|
)
|
|
1,485
|
|
|
(4,876
|
)
|
|
3,672
|
|
||||
Income before income taxes
|
44,244
|
|
|
41,373
|
|
|
131,043
|
|
|
122,393
|
|
||||
Income tax expense
|
(9,919
|
)
|
|
(9,825
|
)
|
|
(31,105
|
)
|
|
(29,984
|
)
|
||||
Net income
|
34,325
|
|
|
31,548
|
|
|
99,938
|
|
|
92,409
|
|
||||
Net income attributable to noncontrolling interests
|
(193
|
)
|
|
(171
|
)
|
|
(760
|
)
|
|
(524
|
)
|
||||
Net income attributable to Amedisys, Inc.
|
$
|
34,132
|
|
|
$
|
31,377
|
|
|
$
|
99,178
|
|
|
$
|
91,885
|
|
Basic earnings per common share:
|
|
|
|
|
|
|
|
||||||||
Net income attributable to Amedisys, Inc. common stockholders
|
$
|
1.06
|
|
|
$
|
0.99
|
|
|
$
|
3.09
|
|
|
$
|
2.78
|
|
Weighted average shares outstanding
|
32,211
|
|
|
31,815
|
|
|
32,096
|
|
|
33,075
|
|
||||
Diluted earnings per common share:
|
|
|
|
|
|
|
|
||||||||
Net income attributable to Amedisys, Inc. common stockholders
|
$
|
1.03
|
|
|
$
|
0.96
|
|
|
$
|
3.01
|
|
|
$
|
2.71
|
|
Weighted average shares outstanding
|
33,002
|
|
|
32,691
|
|
|
32,944
|
|
|
33,852
|
|
|
For the Three-Months Ended September 30, 2019
|
|||||||||||||||||||||||||||||
|
Total
|
|
Common Stock
|
|
Additional
Paid-in
Capital
|
|
Treasury
Stock
|
|
Accumulated
Other
Comprehensive Income
|
|
Retained
Earnings
|
|
Noncontrolling
Interests
|
|||||||||||||||||
Shares
|
|
Amount
|
|
|||||||||||||||||||||||||||
Balance, June 30, 2019
|
$
|
562,942
|
|
|
36,445,591
|
|
|
$
|
36
|
|
|
$
|
623,309
|
|
|
$
|
(246,175
|
)
|
|
$
|
15
|
|
|
$
|
184,596
|
|
|
$
|
1,161
|
|
Issuance of stock – employee stock purchase plan
|
850
|
|
|
8,230
|
|
|
—
|
|
|
850
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Issuance of stock – 401(k) plan
|
2,353
|
|
|
19,381
|
|
|
—
|
|
|
2,353
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Issuance/(cancellation) of non-vested stock
|
—
|
|
|
88,334
|
|
|
1
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Exercise of stock options
|
2,045
|
|
|
37,737
|
|
|
—
|
|
|
2,045
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Non-cash compensation
|
6,298
|
|
|
—
|
|
|
—
|
|
|
6,298
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Surrendered shares
|
(4,895
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(4,895
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Noncontrolling interest distribution
|
(453
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(453
|
)
|
|||||||
Net income
|
34,325
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
34,132
|
|
|
193
|
|
|||||||
Balance, September 30, 2019
|
$
|
603,465
|
|
|
36,599,273
|
|
|
$
|
37
|
|
|
$
|
634,854
|
|
|
$
|
(251,070
|
)
|
|
$
|
15
|
|
|
$
|
218,728
|
|
|
$
|
901
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
For the Three-Months Ended September 30, 2018
|
|||||||||||||||||||||||||||||
|
Total
|
|
Common Stock
|
|
Additional
Paid-in
Capital
|
|
Treasury
Stock
|
|
Accumulated
Other
Comprehensive Income
|
|
Retained
Earnings
|
|
Noncontrolling
Interests
|
|||||||||||||||||
|
Shares
|
|
Amount
|
|
||||||||||||||||||||||||||
Balance, June 30, 2018
|
$
|
409,061
|
|
|
36,044,177
|
|
|
$
|
36
|
|
|
$
|
585,137
|
|
|
$
|
(237,947
|
)
|
|
$
|
15
|
|
|
$
|
60,712
|
|
|
$
|
1,108
|
|
Issuance of stock – employee stock purchase plan
|
630
|
|
|
8,673
|
|
|
—
|
|
|
630
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Issuance of stock – 401(k) plan
|
2,404
|
|
|
28,123
|
|
|
—
|
|
|
2,404
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Issuance/(cancellation) of non-vested stock
|
—
|
|
|
63,098
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Exercise of stock options
|
140
|
|
|
2,578
|
|
|
—
|
|
|
140
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Non-cash compensation
|
4,842
|
|
|
—
|
|
|
—
|
|
|
4,842
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Surrendered shares
|
(2,589
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(2,589
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Noncontrolling interest distribution
|
(180
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(180
|
)
|
|||||||
Repurchase of noncontrolling interest
|
(361
|
)
|
|
—
|
|
|
—
|
|
|
(614
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
253
|
|
|||||||
Net income
|
31,548
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
31,377
|
|
|
171
|
|
|||||||
Balance, September 30, 2018
|
$
|
445,495
|
|
|
36,146,649
|
|
|
$
|
36
|
|
|
$
|
592,539
|
|
|
$
|
(240,536
|
)
|
|
$
|
15
|
|
|
$
|
92,089
|
|
|
$
|
1,352
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
For the Nine-Months Ended September 30, 2019
|
|||||||||||||||||||||||||||||
|
Total
|
|
Common Stock
|
|
Additional
Paid-in
Capital
|
|
Treasury
Stock
|
|
Accumulated
Other
Comprehensive Income
|
|
Retained
Earnings
|
|
Noncontrolling
Interests
|
|||||||||||||||||
|
Shares
|
|
Amount
|
|
||||||||||||||||||||||||||
Balance, December 31, 2018
|
$
|
482,633
|
|
|
36,252,280
|
|
|
$
|
36
|
|
|
$
|
603,666
|
|
|
$
|
(241,685
|
)
|
|
$
|
15
|
|
|
$
|
119,550
|
|
|
$
|
1,051
|
|
Issuance of stock – employee stock purchase plan
|
2,384
|
|
|
23,267
|
|
|
—
|
|
|
2,384
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Issuance of stock – 401(k) plan
|
6,966
|
|
|
57,783
|
|
|
—
|
|
|
6,966
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Issuance/(cancellation) of non-vested stock
|
—
|
|
|
185,515
|
|
|
1
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Exercise of stock options
|
3,388
|
|
|
80,428
|
|
|
—
|
|
|
3,388
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Non-cash compensation
|
18,451
|
|
|
—
|
|
|
—
|
|
|
18,451
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Surrendered shares
|
(9,385
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(9,385
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Noncontrolling interest distribution
|
(910
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(910
|
)
|
|||||||
Net income
|
99,938
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
99,178
|
|
|
760
|
|
|||||||
Balance, September 30, 2019
|
$
|
603,465
|
|
|
36,599,273
|
|
|
$
|
37
|
|
|
$
|
634,854
|
|
|
$
|
(251,070
|
)
|
|
$
|
15
|
|
|
$
|
218,728
|
|
|
$
|
901
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
For the Nine-Months Ended September 30, 2018
|
|||||||||||||||||||||||||||||
|
Total
|
|
Common Stock
|
|
Additional
Paid-in
Capital
|
|
Treasury
Stock
|
|
Accumulated
Other
Comprehensive Income
|
|
Retained
Earnings
|
|
Noncontrolling
Interests
|
|||||||||||||||||
|
Shares
|
|
Amount
|
|
||||||||||||||||||||||||||
Balance, December 31, 2017
|
$
|
516,426
|
|
|
35,747,134
|
|
|
$
|
35
|
|
|
$
|
568,780
|
|
|
$
|
(53,713
|
)
|
|
$
|
15
|
|
|
$
|
204
|
|
|
$
|
1,105
|
|
Issuance of stock – employee stock purchase plan
|
1,787
|
|
|
32,909
|
|
|
—
|
|
|
1,787
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Issuance of stock – 401(k) plan
|
7,185
|
|
|
113,082
|
|
|
—
|
|
|
7,185
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Issuance/(cancellation) of non-vested stock
|
—
|
|
|
169,811
|
|
|
1
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Exercise of stock options
|
2,749
|
|
|
83,713
|
|
|
—
|
|
|
2,749
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Non-cash compensation
|
12,653
|
|
|
—
|
|
|
—
|
|
|
12,653
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Surrendered shares
|
(5,421
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(5,421
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Shares repurchased
|
(181,402
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(181,402
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
Noncontrolling interest distribution
|
(530
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(530
|
)
|
|||||||
Repurchase of noncontrolling interest
|
(361
|
)
|
|
—
|
|
|
—
|
|
|
(614
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
253
|
|
|||||||
Net income
|
92,409
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
91,885
|
|
|
524
|
|
|||||||
Balance, September 30, 2018
|
$
|
445,495
|
|
|
36,146,649
|
|
|
$
|
36
|
|
|
$
|
592,539
|
|
|
$
|
(240,536
|
)
|
|
$
|
15
|
|
|
$
|
92,089
|
|
|
$
|
1,352
|
|
|
For the Nine-Month
Periods Ended September 30 |
||||||
|
2019
|
|
2018
|
||||
Cash Flows from Operating Activities:
|
|
|
|
||||
Net income
|
$
|
99,938
|
|
|
$
|
92,409
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
||||
Depreciation and amortization
|
12,440
|
|
|
9,882
|
|
||
Non-cash compensation
|
18,451
|
|
|
12,653
|
|
||
401(k) employer match
|
7,545
|
|
|
6,934
|
|
||
Amortization and impairment of operating lease right of use assets
|
27,014
|
|
|
—
|
|
||
Loss on disposal of property and equipment
|
6
|
|
|
738
|
|
||
Deferred income taxes
|
17,798
|
|
|
14,916
|
|
||
Equity in earnings from equity method investments
|
(4,120
|
)
|
|
(6,461
|
)
|
||
Amortization of deferred debt issuance costs/debt discount
|
653
|
|
|
596
|
|
||
Return on equity investment
|
3,727
|
|
|
4,373
|
|
||
Changes in operating assets and liabilities, net of impact of acquisitions:
|
|
|
|
||||
Patient accounts receivable
|
(39,469
|
)
|
|
6,166
|
|
||
Other current assets
|
(10,194
|
)
|
|
(32
|
)
|
||
Other assets
|
202
|
|
|
726
|
|
||
Accounts payable
|
(8,145
|
)
|
|
(670
|
)
|
||
Accrued expenses
|
27,903
|
|
|
14,758
|
|
||
Other long-term obligations
|
(231
|
)
|
|
2,462
|
|
||
Operating lease liabilities
|
(24,116
|
)
|
|
—
|
|
||
Operating lease right of use assets
|
(2,622
|
)
|
|
—
|
|
||
Net cash provided by operating activities
|
126,780
|
|
|
159,450
|
|
||
Cash Flows from Investing Activities:
|
|
|
|
||||
Proceeds from sale of deferred compensation plan assets
|
287
|
|
|
563
|
|
||
Proceeds from the sale of property and equipment
|
158
|
|
|
51
|
|
||
Investments in equity method investees
|
(210
|
)
|
|
(3,477
|
)
|
||
Purchases of property and equipment
|
(6,337
|
)
|
|
(5,684
|
)
|
||
Acquisitions of businesses, net of cash acquired
|
(345,460
|
)
|
|
(4,074
|
)
|
||
Net cash used in investing activities
|
(351,562
|
)
|
|
(12,621
|
)
|
||
Cash Flows from Financing Activities:
|
|
|
|
||||
Proceeds from issuance of stock upon exercise of stock options
|
3,388
|
|
|
2,749
|
|
||
Proceeds from issuance of stock to employee stock purchase plan
|
2,384
|
|
|
1,787
|
|
||
Shares withheld upon stock vesting
|
(9,385
|
)
|
|
(5,421
|
)
|
||
Noncontrolling interest distribution
|
(910
|
)
|
|
(530
|
)
|
||
Proceeds from borrowings under term loan
|
175,000
|
|
|
—
|
|
||
Proceeds from borrowings under revolving line of credit
|
192,500
|
|
|
127,500
|
|
||
Repayments of borrowings under revolving line of credit
|
(133,000
|
)
|
|
(70,000
|
)
|
||
Principal payments of long-term obligations
|
(3,820
|
)
|
|
(91,071
|
)
|
||
Debt issuance costs
|
(847
|
)
|
|
(2,433
|
)
|
||
Purchase of company stock
|
—
|
|
|
(181,402
|
)
|
||
Repurchase of noncontrolling interest
|
—
|
|
|
(361
|
)
|
||
Net cash provided by (used in) financing activities
|
225,310
|
|
|
(219,182
|
)
|
||
Net increase (decrease) in cash and cash equivalents
|
528
|
|
|
(72,353
|
)
|
||
Cash and cash equivalents at beginning of period
|
20,229
|
|
|
86,363
|
|
||
Cash and cash equivalents at end of period
|
$
|
20,757
|
|
|
$
|
14,010
|
|
Supplemental Disclosures of Cash Flow Information:
|
|
|
|
||||
Cash paid for interest
|
$
|
7,756
|
|
|
$
|
2,989
|
|
Cash paid for income taxes, net of refunds received
|
$
|
17,656
|
|
|
$
|
11,017
|
|
|
Fair Value at Reporting Date Using
|
||||||||||||||
Financial Instrument
|
Carrying Value as of
September 30, 2019 |
|
Quoted Prices in Active
Markets for Identical
Items
(Level 1)
|
|
Significant Other
Observable Inputs
(Level 2)
|
|
Significant
Unobservable Inputs
(Level 3)
|
||||||||
Long-term obligations
|
$
|
240.6
|
|
|
$
|
—
|
|
|
$
|
236.0
|
|
|
$
|
—
|
|
•
|
Level 1 – Quoted prices in active markets for identical assets and liabilities.
|
•
|
Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
|
•
|
Level 3 – Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.
|
|
For the Three-
Month Periods
Ended September 30,
|
|
For the Nine-
Month Periods Ended September 30, |
||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||
Weighted average number of shares outstanding - basic
|
32,211
|
|
|
31,815
|
|
|
32,096
|
|
|
33,075
|
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
||||
Stock options
|
532
|
|
|
561
|
|
|
543
|
|
|
464
|
|
Non-vested stock and stock units
|
259
|
|
|
315
|
|
|
305
|
|
|
313
|
|
Weighted average number of shares outstanding - diluted
|
33,002
|
|
|
32,691
|
|
|
32,944
|
|
|
33,852
|
|
Anti-dilutive securities
|
133
|
|
|
51
|
|
|
154
|
|
|
76
|
|
|
Amount
|
||
Patient accounts receivable
|
$
|
26.3
|
|
Prepaid expenses
|
0.8
|
|
|
Other current assets
|
0.2
|
|
|
Property and equipment
|
0.2
|
|
|
Intangible assets
|
24.4
|
|
|
Operating lease right of use assets
|
3.4
|
|
|
Total assets acquired
|
55.3
|
|
|
Accounts payable
|
(15.9
|
)
|
|
Payroll and employee benefits
|
(11.8
|
)
|
|
Accrued expenses
|
(11.0
|
)
|
|
Deferred tax liability
|
(0.4
|
)
|
|
Operating lease liabilities
|
(3.4
|
)
|
|
Total liabilities acquired
|
(42.5
|
)
|
|
Net identifiable assets acquired
|
12.8
|
|
|
Goodwill
|
315.1
|
|
|
Total estimated consideration
|
$
|
327.9
|
|
|
For the Three-
Month Periods Ended September 30, |
|
For the Nine-
Month Periods
Ended September 30,
|
||||||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Net service revenue
|
$
|
494.6
|
|
|
$
|
467.3
|
|
|
$
|
1,471.0
|
|
|
$
|
1,373.4
|
|
Operating income
|
46.8
|
|
|
47.0
|
|
|
142.2
|
|
|
136.9
|
|
||||
Net income attributable to Amedisys, Inc.
|
34.1
|
|
|
34.2
|
|
|
102.9
|
|
|
97.9
|
|
||||
Basic earnings per share
|
1.06
|
|
|
1.07
|
|
|
3.21
|
|
|
2.96
|
|
||||
Diluted earnings per share
|
$
|
1.03
|
|
|
$
|
1.05
|
|
|
$
|
3.12
|
|
|
$
|
2.89
|
|
|
For the
Three-Month Period Ended September 30, 2019
|
|
For the
Nine-Month Period Ended September 30, 2019
|
||||
Operating lease cost:
|
|
|
|
||||
Operating lease cost
|
$
|
8.8
|
|
|
$
|
26.0
|
|
Impairment of operating lease ROU assets
|
0.7
|
|
|
1.0
|
|
||
Total operating lease cost
|
9.5
|
|
|
27.0
|
|
||
|
|
|
|
||||
Finance lease cost:
|
|
|
|
||||
Amortization of ROU assets
|
0.5
|
|
|
1.3
|
|
||
Interest on lease liabilities
|
—
|
|
|
0.1
|
|
||
Total finance lease cost
|
0.5
|
|
|
1.4
|
|
||
|
|
|
|
||||
Variable lease cost
|
0.7
|
|
|
1.9
|
|
||
Short-term lease cost
|
0.1
|
|
|
0.2
|
|
||
|
|
|
|
||||
Total lease cost
|
$
|
10.8
|
|
|
$
|
30.5
|
|
|
September 30, 2019
|
||
Operating lease ROU assets
|
$
|
84.1
|
|
|
|
||
Current portion of operating lease liabilities
|
26.8
|
|
|
Operating lease liabilities, less current portion
|
56.6
|
|
|
Total operating lease liabilities
|
$
|
83.4
|
|
|
September 30, 2019
|
||
Finance lease ROU assets
|
$
|
5.1
|
|
Accumulated amortization
|
(1.4
|
)
|
|
Finance lease ROU assets, net
|
3.7
|
|
|
|
|
||
Current installments of obligations under finance leases
|
1.7
|
|
|
Long-term portion of obligations under finance leases
|
2.0
|
|
|
Total finance lease liabilities
|
$
|
3.7
|
|
|
Years
|
|
Weighted average remaining lease term:
|
|
|
Operating leases
|
4.0
|
|
Finance leases
|
2.3
|
|
|
Rate
|
|
Weighted average discount rate:
|
|
|
Operating leases
|
4.0
|
%
|
Finance leases
|
5.3
|
%
|
|
Operating
Leases
|
|
Finance
Leases
|
||||
2019 (a)
|
$
|
6.3
|
|
|
$
|
0.5
|
|
2020
|
29.8
|
|
|
1.8
|
|
||
2021
|
22.1
|
|
|
1.4
|
|
||
2022
|
13.1
|
|
|
0.2
|
|
||
2023
|
8.2
|
|
|
—
|
|
||
Thereafter
|
11.0
|
|
|
—
|
|
||
Total undiscounted lease payments
|
90.5
|
|
|
3.9
|
|
||
Less: Imputed interest
|
(7.1
|
)
|
|
(0.2
|
)
|
||
Total lease liabilities
|
$
|
83.4
|
|
|
$
|
3.7
|
|
|
September 30, 2019
|
|
December 31, 2018
|
||||
$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.6% at September 30, 2019); due February 4, 2024
|
$
|
172.8
|
|
|
$
|
—
|
|
$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (3.5% at September 30, 2019); due February 4, 2024
|
67.0
|
|
|
7.5
|
|
||
Promissory notes
|
0.8
|
|
|
1.1
|
|
||
Finance leases
|
3.7
|
|
|
2.3
|
|
||
Principal amount of long-term obligations
|
244.3
|
|
|
10.9
|
|
||
Deferred debt issuance costs
|
(3.7
|
)
|
|
(3.5
|
)
|
||
|
240.6
|
|
|
7.4
|
|
||
Current portion of long-term obligations
|
(9.0
|
)
|
|
(1.6
|
)
|
||
Total
|
$
|
231.6
|
|
|
$
|
5.8
|
|
|
For the Three-Month Period Ended September 30, 2019
|
||||||||||||||||||
|
Home
Health
|
|
Hospice
|
|
Personal
Care
|
|
Other
|
|
Total
|
||||||||||
Net service revenue
|
$
|
311.5
|
|
|
$
|
162.4
|
|
|
$
|
20.7
|
|
|
$
|
—
|
|
|
$
|
494.6
|
|
Cost of service, excluding depreciation and amortization
|
188.9
|
|
|
84.5
|
|
|
15.3
|
|
|
—
|
|
|
288.7
|
|
|||||
General and administrative expenses
|
75.5
|
|
|
35.8
|
|
|
3.0
|
|
|
40.4
|
|
|
154.7
|
|
|||||
Depreciation and amortization
|
1.0
|
|
|
0.4
|
|
|
0.1
|
|
|
2.9
|
|
|
4.4
|
|
|||||
Operating expenses
|
265.4
|
|
|
120.7
|
|
|
18.4
|
|
|
43.3
|
|
|
447.8
|
|
|||||
Operating income (loss)
|
$
|
46.1
|
|
|
$
|
41.7
|
|
|
$
|
2.3
|
|
|
$
|
(43.3
|
)
|
|
$
|
46.8
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
For the Three-Month Period Ended September 30, 2018
|
||||||||||||||||||
|
Home
Health
|
|
Hospice
|
|
Personal
Care
|
|
Other
|
|
Total
|
||||||||||
Net service revenue
|
$
|
294.9
|
|
|
$
|
103.4
|
|
|
$
|
19.0
|
|
|
$
|
—
|
|
|
$
|
417.3
|
|
Cost of service, excluding depreciation and amortization
|
181.8
|
|
|
53.4
|
|
|
14.5
|
|
|
—
|
|
|
249.7
|
|
|||||
General and administrative expenses
|
68.8
|
|
|
21.4
|
|
|
3.0
|
|
|
31.3
|
|
|
124.5
|
|
|||||
Depreciation and amortization
|
0.8
|
|
|
0.3
|
|
|
0.1
|
|
|
2.0
|
|
|
3.2
|
|
|||||
Operating expenses
|
251.4
|
|
|
75.1
|
|
|
17.6
|
|
|
33.3
|
|
|
377.4
|
|
|||||
Operating income (loss)
|
$
|
43.5
|
|
|
$
|
28.3
|
|
|
$
|
1.4
|
|
|
$
|
(33.3
|
)
|
|
$
|
39.9
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
For the Nine-Month Period Ended September 30, 2019
|
||||||||||||||||||
|
Home
Health
|
|
Hospice
|
|
Personal
Care
|
|
Other
|
|
Total
|
||||||||||
Net service revenue
|
$
|
940.2
|
|
|
$
|
452.6
|
|
|
$
|
62.1
|
|
|
$
|
—
|
|
|
$
|
1,454.9
|
|
Cost of service, excluding depreciation and amortization
|
562.4
|
|
|
245.9
|
|
|
46.4
|
|
|
—
|
|
|
854.7
|
|
|||||
General and administrative expenses
|
220.9
|
|
|
99.7
|
|
|
9.3
|
|
|
122.0
|
|
|
451.9
|
|
|||||
Depreciation and amortization
|
3.1
|
|
|
1.2
|
|
|
0.2
|
|
|
7.9
|
|
|
12.4
|
|
|||||
Operating expenses
|
786.4
|
|
|
346.8
|
|
|
55.9
|
|
|
129.9
|
|
|
1,319.0
|
|
|||||
Operating income (loss)
|
$
|
153.8
|
|
|
$
|
105.8
|
|
|
$
|
6.2
|
|
|
$
|
(129.9
|
)
|
|
$
|
135.9
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
For the Nine-Month Period Ended September 30, 2018
|
||||||||||||||||||
|
Home
Health
|
|
Hospice
|
|
Personal
Care
|
|
Other
|
|
Total
|
||||||||||
Net service revenue
|
$
|
870.5
|
|
|
$
|
302.1
|
|
|
$
|
55.6
|
|
|
$
|
—
|
|
|
$
|
1,228.2
|
|
Cost of service, excluding depreciation and amortization
|
532.7
|
|
|
155.2
|
|
|
42.7
|
|
|
—
|
|
|
730.6
|
|
|||||
General and administrative expenses
|
205.2
|
|
|
61.7
|
|
|
9.5
|
|
|
92.6
|
|
|
369.0
|
|
|||||
Depreciation and amortization
|
2.4
|
|
|
0.8
|
|
|
0.2
|
|
|
6.5
|
|
|
9.9
|
|
|||||
Operating expenses
|
740.3
|
|
|
217.7
|
|
|
52.4
|
|
|
99.1
|
|
|
1,109.5
|
|
|||||
Operating income (loss)
|
$
|
130.2
|
|
|
$
|
84.4
|
|
|
$
|
3.2
|
|
|
$
|
(99.1
|
)
|
|
$
|
118.7
|
|
|
Home
Health
|
|
Hospice
|
|
Personal
Care
|
|||
As of December 31, 2018
|
323
|
|
|
84
|
|
|
12
|
|
Acquisitions/Startups
|
3
|
|
|
57
|
|
|
—
|
|
Closed/Consolidated
|
(5
|
)
|
|
(4
|
)
|
|
—
|
|
As of September 30, 2019
|
321
|
|
|
137
|
|
|
12
|
|
|
For the Three-Month Periods
Ended September 30,
|
||||||
|
2019
|
|
2018
|
||||
Net service revenue
|
$
|
494.6
|
|
|
$
|
417.3
|
|
Gross margin, excluding depreciation and amortization
|
205.9
|
|
|
167.6
|
|
||
% of revenue
|
41.6
|
%
|
|
40.2
|
%
|
||
Other operating expenses
|
154.7
|
|
|
124.5
|
|
||
% of revenue
|
31.3
|
%
|
|
29.8
|
%
|
||
Depreciation and amortization
|
4.4
|
|
|
3.2
|
|
||
Operating income
|
46.8
|
|
|
39.9
|
|
||
Total other (expense) income, net
|
(2.6
|
)
|
|
1.5
|
|
||
Income tax expense
|
(9.9
|
)
|
|
(9.8
|
)
|
||
Effective income tax rate
|
22.4
|
%
|
|
23.7
|
%
|
||
Net income
|
34.3
|
|
|
31.6
|
|
||
Net income attributable to noncontrolling interests
|
(0.2
|
)
|
|
(0.2
|
)
|
||
Net income attributable to Amedisys, Inc.
|
$
|
34.1
|
|
|
$
|
31.4
|
|
|
For the Three-Month Periods
Ended September 30, |
||||||
|
2019
|
|
2018
|
||||
Financial Information (in millions):
|
|
|
|
||||
Medicare
|
$
|
211.5
|
|
|
$
|
208.0
|
|
Non-Medicare
|
100.0
|
|
|
86.9
|
|
||
Net service revenue
|
311.5
|
|
|
294.9
|
|
||
Cost of service
|
188.9
|
|
|
181.8
|
|
||
Gross margin
|
122.6
|
|
|
113.1
|
|
||
Other operating expenses
|
76.5
|
|
|
69.6
|
|
||
Operating income
|
$
|
46.1
|
|
|
$
|
43.5
|
|
Same Store Growth (1):
|
|
|
|
||||
Medicare revenue
|
2
|
%
|
|
10
|
%
|
||
Non-Medicare revenue
|
16
|
%
|
|
20
|
%
|
||
Total admissions
|
9
|
%
|
|
4
|
%
|
||
Total volume (2)
|
6
|
%
|
|
6
|
%
|
||
Total Episodic admissions (3)
|
8
|
%
|
|
3
|
%
|
||
Total Episodic volume (4)
|
5
|
%
|
|
5
|
%
|
||
Key Statistical Data - Total (5):
|
|
|
|
||||
Medicare:
|
|
|
|
||||
Admissions
|
48,295
|
|
|
46,371
|
|
||
Recertifications
|
27,662
|
|
|
28,551
|
|
||
Total volume
|
75,957
|
|
|
74,922
|
|
||
Completed episodes
|
74,355
|
|
|
73,114
|
|
||
Visits
|
1,281,380
|
|
|
1,301,090
|
|
||
Average revenue per completed episode (6)
|
$
|
2,909
|
|
|
$
|
2,855
|
|
Visits per completed episode (7)
|
17.1
|
|
|
17.6
|
|
||
Non-Medicare:
|
|
|
|
||||
Admissions
|
33,642
|
|
|
29,325
|
|
||
Recertifications
|
15,678
|
|
|
14,539
|
|
||
Total volume
|
49,320
|
|
|
43,864
|
|
||
Visits
|
775,804
|
|
|
698,181
|
|
||
Total (5):
|
|
|
|
||||
Visiting Clinician Cost per Visit
|
$
|
83.68
|
|
|
$
|
82.78
|
|
Clinical Manager Cost per Visit
|
$
|
8.09
|
|
|
$
|
8.18
|
|
Total Cost per Visit
|
$
|
91.77
|
|
|
$
|
90.96
|
|
Visits
|
2,057,184
|
|
|
1,999,271
|
|
(1)
|
Same store information represents the percent change in our Medicare, Non-Medicare, Total and Episodic revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare, Total and Episodic revenue, admissions or volume of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
|
(2)
|
Total volume includes all admissions and recertifications.
|
(3)
|
Total Episodic admissions includes admissions for Medicare and Non-Medicare payors that bill on a 60-day episode of care basis.
|
(4)
|
Total Episodic volume includes admissions and recertifications for Medicare and Non-Medicare payors that bill on a 60-day episode of care basis.
|
(5)
|
Total includes acquisitions and denovos.
|
(6)
|
Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care.
|
(7)
|
Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.
|
|
For the Three-Month Periods
Ended September 30, |
||||||
|
2019
|
|
2018
|
||||
Financial Information (in millions):
|
|
|
|
||||
Medicare
|
$
|
153.5
|
|
|
$
|
98.0
|
|
Non-Medicare
|
8.9
|
|
|
5.4
|
|
||
Net service revenue
|
162.4
|
|
|
103.4
|
|
||
Cost of service
|
84.5
|
|
|
53.4
|
|
||
Gross margin
|
77.9
|
|
|
50.0
|
|
||
Other operating expenses
|
36.2
|
|
|
21.7
|
|
||
Operating income
|
$
|
41.7
|
|
|
$
|
28.3
|
|
Same Store Growth (1):
|
|
|
|
||||
Medicare revenue
|
10
|
%
|
|
7
|
%
|
||
Hospice admissions
|
4
|
%
|
|
8
|
%
|
||
Average daily census
|
5
|
%
|
|
11
|
%
|
||
Key Statistical Data - Total (2):
|
|
|
|
||||
Hospice admissions
|
9,914
|
|
|
6,765
|
|
||
Average daily census
|
11,565
|
|
|
7,768
|
|
||
Revenue per day, net
|
$
|
152.67
|
|
|
$
|
144.71
|
|
Cost of service per day
|
$
|
79.51
|
|
|
$
|
74.72
|
|
Average discharge length of stay
|
98
|
|
|
101
|
|
(1)
|
Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
|
(2)
|
Total includes acquisitions and denovos.
|
|
For the Three-Month Periods
Ended September 30, |
||||||
|
2019
|
|
2018
|
||||
Financial Information (in millions):
|
|
|
|
||||
Medicare
|
$
|
—
|
|
|
$
|
—
|
|
Non-Medicare
|
20.7
|
|
|
19.0
|
|
||
Net service revenue
|
20.7
|
|
|
19.0
|
|
||
Cost of service
|
15.3
|
|
|
14.5
|
|
||
Gross margin
|
5.4
|
|
|
4.5
|
|
||
Other operating expenses
|
3.1
|
|
|
3.1
|
|
||
Operating income
|
$
|
2.3
|
|
|
$
|
1.4
|
|
Key Statistical Data - Total (1):
|
|
|
|
||||
Billable hours
|
824,251
|
|
|
810,427
|
|
||
Clients served
|
12,687
|
|
|
12,380
|
|
||
Shifts
|
370,451
|
|
|
357,382
|
|
||
Revenue per hour
|
$
|
25.12
|
|
|
$
|
23.40
|
|
Revenue per shift
|
$
|
55.90
|
|
|
$
|
53.06
|
|
Hours per shift
|
2.2
|
|
|
2.3
|
|
(1)
|
Total includes acquisitions.
|
|
For the Three-Month Periods
Ended September 30, |
||||||
|
2019
|
|
2018
|
||||
Financial Information (in millions):
|
|
|
|
||||
Other operating expenses
|
$
|
40.4
|
|
|
$
|
31.3
|
|
Depreciation and amortization
|
2.9
|
|
|
2.0
|
|
||
Total operating expenses
|
$
|
43.3
|
|
|
$
|
33.3
|
|
|
For the Nine-Month Periods
Ended September 30,
|
||||||
|
2019
|
|
2018
|
||||
Net service revenue
|
$
|
1,454.9
|
|
|
$
|
1,228.2
|
|
Gross margin, excluding depreciation and amortization
|
600.2
|
|
|
497.6
|
|
||
% of revenue
|
41.3
|
%
|
|
40.5
|
%
|
||
Other operating expenses
|
451.9
|
|
|
369.0
|
|
||
% of revenue
|
31.1
|
%
|
|
30.0
|
%
|
||
Depreciation and amortization
|
12.4
|
|
|
9.9
|
|
||
Operating income
|
135.9
|
|
|
118.7
|
|
||
Total other (expense) income, net
|
(4.9
|
)
|
|
3.7
|
|
||
Income tax expense
|
(31.1
|
)
|
|
(30.0
|
)
|
||
Effective income tax rate
|
23.7
|
%
|
|
24.5
|
%
|
||
Net income
|
99.9
|
|
|
92.4
|
|
||
Net income attributable to noncontrolling interests
|
(0.7
|
)
|
|
(0.5
|
)
|
||
Net income attributable to Amedisys, Inc.
|
$
|
99.2
|
|
|
$
|
91.9
|
|
|
For the Nine-Month Periods
Ended September 30, |
||||||
|
2019
|
|
2018
|
||||
Financial Information (in millions):
|
|
|
|
||||
Medicare
|
$
|
644.0
|
|
|
$
|
619.3
|
|
Non-Medicare
|
296.2
|
|
|
251.2
|
|
||
Net service revenue
|
940.2
|
|
|
870.5
|
|
||
Cost of service
|
562.4
|
|
|
532.7
|
|
||
Gross margin
|
377.8
|
|
|
337.8
|
|
||
Other operating expenses
|
224.0
|
|
|
207.6
|
|
||
Operating income
|
$
|
153.8
|
|
|
$
|
130.2
|
|
Same Store Growth (1):
|
|
|
|
||||
Medicare revenue
|
4
|
%
|
|
7
|
%
|
||
Non-Medicare revenue
|
18
|
%
|
|
18
|
%
|
||
Total admissions
|
7
|
%
|
|
4
|
%
|
||
Total volume (2)
|
6
|
%
|
|
7
|
%
|
||
Total Episodic admissions (3)
|
6
|
%
|
|
3
|
%
|
||
Total Episodic volume (4)
|
4
|
%
|
|
6
|
%
|
||
Key Statistical Data - Total (5):
|
|
|
|
||||
Medicare:
|
|
|
|
||||
Admissions
|
147,485
|
|
|
142,884
|
|
||
Recertifications
|
82,551
|
|
|
84,218
|
|
||
Total volume
|
230,036
|
|
|
227,102
|
|
||
Completed episodes
|
224,635
|
|
|
220,726
|
|
||
Visits
|
3,935,182
|
|
|
3,933,290
|
|
||
Average revenue per completed episode (6)
|
$
|
2,922
|
|
|
$
|
2,841
|
|
Visits per completed episode (7)
|
17.4
|
|
|
17.5
|
|
||
Non-Medicare:
|
|
|
|
||||
Admissions
|
100,184
|
|
|
88,485
|
|
||
Recertifications
|
45,945
|
|
|
40,862
|
|
||
Total volume
|
146,129
|
|
|
129,347
|
|
||
Visits
|
2,303,576
|
|
|
2,049,662
|
|
||
Total (5):
|
|
|
|
||||
Visiting Clinician Cost per Visit
|
$
|
82.23
|
|
|
$
|
81.06
|
|
Clinical Manager Cost per Visit
|
7.91
|
|
|
7.98
|
|
||
Total Cost per Visit
|
$
|
90.14
|
|
|
$
|
89.04
|
|
Visits
|
6,238,758
|
|
|
5,982,952
|
|
(1)
|
Same store information represents the percent change in our Medicare, Non-Medicare, Total and Episodic revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare, Total and Episodic revenue, admissions or volume of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
|
(2)
|
Total volume includes all admissions and recertifications.
|
(3)
|
Total Episodic admissions includes admissions for Medicare and Non-Medicare payors that bill on a 60-day episode of care basis.
|
(4)
|
Total Episodic volume includes admissions and recertifications for Medicare and Non-Medicare payors that bill on a 60-day episode of care basis.
|
(5)
|
Total includes acquisitions and denovos.
|
(6)
|
Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care.
|
(7)
|
Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.
|
|
For the Nine-Month Periods
Ended September 30, |
||||||
|
2019
|
|
2018
|
||||
Financial Information (in millions):
|
|
|
|
||||
Medicare
|
$
|
430.0
|
|
|
$
|
286.7
|
|
Non-Medicare
|
22.6
|
|
|
15.4
|
|
||
Net service revenue
|
452.6
|
|
|
302.1
|
|
||
Cost of service
|
245.9
|
|
|
155.2
|
|
||
Gross margin
|
206.7
|
|
|
146.9
|
|
||
Other operating expenses
|
100.9
|
|
|
62.5
|
|
||
Operating income
|
$
|
105.8
|
|
|
$
|
84.4
|
|
Same Store Growth (1):
|
|
|
|
||||
Medicare revenue
|
6
|
%
|
|
11
|
%
|
||
Hospice admissions
|
5
|
%
|
|
7
|
%
|
||
Average daily census
|
6
|
%
|
|
12
|
%
|
||
Key Statistical Data - Total (2):
|
|
|
|
||||
Hospice admissions
|
30,055
|
|
|
20,444
|
|
||
Average daily census
|
10,997
|
|
|
7,514
|
|
||
Revenue per day, net
|
$
|
150.77
|
|
|
$
|
147.28
|
|
Cost of service per day
|
$
|
81.92
|
|
|
$
|
75.65
|
|
Average discharge length of stay
|
98
|
|
|
98
|
|
(1)
|
Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
|
(2)
|
Total includes acquisitions and denovos.
|
|
For the Nine-Month Periods
Ended September 30, |
||||||
|
2019
|
|
2018
|
||||
Financial Information (in millions):
|
|
|
|
||||
Medicare
|
$
|
—
|
|
|
$
|
—
|
|
Non-Medicare
|
62.1
|
|
|
55.6
|
|
||
Net service revenue
|
62.1
|
|
|
55.6
|
|
||
Cost of service
|
46.4
|
|
|
42.7
|
|
||
Gross margin
|
15.7
|
|
|
12.9
|
|
||
Other operating expenses
|
9.5
|
|
|
9.7
|
|
||
Operating income
|
$
|
6.2
|
|
|
$
|
3.2
|
|
Key Statistical Data - Total (1):
|
|
|
|
||||
Billable hours
|
2,506,113
|
|
|
2,357,608
|
|
||
Clients served
|
16,134
|
|
|
15,731
|
|
||
Shifts
|
1,128,920
|
|
|
1,062,422
|
|
||
Revenue per hour
|
$
|
24.77
|
|
|
$
|
23.57
|
|
Revenue per shift
|
$
|
55.00
|
|
|
$
|
52.30
|
|
Hours per shift
|
2.2
|
|
|
2.2
|
|
(1)
|
Total includes acquisitions.
|
|
For the Nine-Month Periods
Ended September 30, |
||||||
|
2019
|
|
2018
|
||||
Financial Information (in millions):
|
|
|
|
||||
Other operating expenses
|
$
|
122.0
|
|
|
$
|
92.6
|
|
Depreciation and amortization
|
7.9
|
|
|
6.5
|
|
||
Total operating expenses
|
$
|
129.9
|
|
|
$
|
99.1
|
|
|
For the Nine-Month Periods
Ended September 30,
|
||||||
|
2019
|
|
2018
|
||||
Cash provided by operating activities
|
$
|
126.8
|
|
|
$
|
159.4
|
|
Cash used in investing activities
|
(351.5
|
)
|
|
(12.6
|
)
|
||
Cash provided by (used in) financing activities
|
225.3
|
|
|
(219.2
|
)
|
||
Net increase (decrease) in cash and cash equivalents
|
0.6
|
|
|
(72.4
|
)
|
||
Cash and cash equivalents at beginning of period
|
20.2
|
|
|
86.4
|
|
||
Cash and cash equivalents at end of period
|
$
|
20.8
|
|
|
$
|
14.0
|
|
|
0-90
|
|
91-180
|
|
181-365
|
|
Over 365
|
|
Total
|
||||||||||
At September 30, 2019:
|
|
|
|
|
|
|
|
|
|
||||||||||
Medicare patient accounts receivable
|
$
|
125.4
|
|
|
$
|
18.8
|
|
|
$
|
4.0
|
|
|
$
|
0.9
|
|
|
$
|
149.1
|
|
Other patient accounts receivable:
|
|
|
|
|
|
|
|
|
|
||||||||||
Medicaid
|
22.7
|
|
|
6.9
|
|
|
3.4
|
|
|
—
|
|
|
33.0
|
|
|||||
Private
|
62.4
|
|
|
7.2
|
|
|
3.0
|
|
|
—
|
|
|
72.6
|
|
|||||
Total
|
$
|
85.1
|
|
|
$
|
14.1
|
|
|
$
|
6.4
|
|
|
$
|
—
|
|
|
$
|
105.6
|
|
Total patient accounts receivable
|
|
|
|
|
|
|
|
|
$
|
254.7
|
|
||||||||
Days revenue outstanding (1)
|
|
|
|
|
|
|
|
|
44.5
|
|
|||||||||
|
0-90
|
|
91-180
|
|
181-365
|
|
Over 365
|
|
Total
|
||||||||||
At December 31, 2018:
|
|
|
|
|
|
|
|
|
|
||||||||||
Medicare patient accounts receivable
|
$
|
95.5
|
|
|
$
|
8.1
|
|
|
$
|
1.0
|
|
|
$
|
1.8
|
|
|
$
|
106.4
|
|
Other patient accounts receivable:
|
|
|
|
|
|
|
|
|
|
||||||||||
Medicaid
|
13.1
|
|
|
2.7
|
|
|
1.1
|
|
|
—
|
|
|
16.9
|
|
|||||
Private
|
51.3
|
|
|
6.7
|
|
|
4.4
|
|
|
3.3
|
|
|
65.7
|
|
|||||
Total
|
$
|
64.4
|
|
|
$
|
9.4
|
|
|
$
|
5.5
|
|
|
$
|
3.3
|
|
|
$
|
82.6
|
|
Total patient accounts receivable
|
|
|
|
|
|
|
|
|
$
|
189.0
|
|
||||||||
Days revenue outstanding (1)
|
|
|
|
|
|
|
|
|
38.0
|
|
(1)
|
Our calculation of days revenue outstanding is derived by dividing our ending patient accounts receivable at September 30, 2019 and December 31, 2018 by our average daily patient revenue for the three-month periods ended September 30, 2019 and December 31, 2018, respectively.
|
Period
|
(a) Total Number
of Shares (or Units)
Purchased
|
|
|
(b) Average Price
Paid per Share (or
Unit)
|
|
(c) Total Number of
Shares (or Units)
Purchased as Part of
Publicly Announced
Plans or Programs
|
|
(d) Maximum Number (or
Approximate Dollar
Value) of Shares (or
Units) That May Yet Be
Purchased Under the
Plans or Programs
|
||||||
July 1, 2019 to July 31, 2019
|
37,291
|
|
|
|
$
|
131.27
|
|
|
—
|
|
|
$
|
—
|
|
August 1, 2019 to August 31, 2019
|
—
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||
September 1, 2019 to September 30, 2019
|
—
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||
|
37,291
|
|
(1)
|
|
$
|
131.27
|
|
|
—
|
|
|
$
|
—
|
|
(1)
|
Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding obligations in connection with the vesting of non-vested stock previously awarded to such employees under our 2008 and 2018 Omnibus Incentive Compensation Plans.
|
|
|
|
AMEDISYS, INC.
(Registrant)
|
||
|
|
|
By:
|
|
/s/ SCOTT G. GINN
|
|
|
Scott G. Ginn,
|
|
|
Principal Financial Officer and
|
|
|
Duly Authorized Officer
|
(a)
|
No business (including nominating persons to be elected or re-elected to the Corporation’s Board of Directors) may be transacted at an annual meeting of the Corporation’s stockholders other than business that is:
|
(i)
|
specified in a notice of meeting (or any supplement thereto) given by or at the direction of the Corporation’s Board of Directors or an authorized committee thereof;
|
(ii)
|
otherwise brought before the meeting by or at the direction of the Corporation’s Board of Directors or an authorized committee thereof; or
|
(iii)
|
otherwise brought before the meeting:
|
(A)
|
by a stockholder who was a stockholder of record at the time of giving notice provided in Section 2.8 and at the time of the meeting and who is entitled to vote at the meeting on such business (including electing or re-electing persons to the Corporation’s Board of Directors) (a “Record Holder”); and
|
(B)
|
who complies with the notice procedures set forth in Section 2.8 (any such Record Holder being hereafter referred to as a “Noticing Stockholder”).
|
(b)
|
Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation’s notice of meeting (or any supplement thereto). Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which directors are to be elected or re-elected pursuant to the Corporation’s notice of meeting only:
|
(i)
|
by or at the direction of the Corporation’s Board of Directors or an authorized committee thereof; or
|
(ii)
|
provided that the Board of Directors has determined that directors are to be elected at such special meeting, by a Noticing Stockholder who complies with the notice procedures set forth in Section 2.8.
|
(a)
|
To be timely, a Noticing Stockholder’s notice required by these By-Laws must be delivered to the Secretary at the Corporation’s principal executive offices in proper written form:
|
(i)
|
Annual Meeting Deadlines. In connection with business (including nominating persons to be elected or re-elected to the Corporation’s Board of Directors) to be properly brought at an annual meeting of stockholders in accordance with Section 2.3(a), not earlier than the close of business on the one hundred twentieth (120th) day and not later than the close of business on the ninetieth (90th) day prior to the first anniversary of the preceding year’s annual meeting; provided, however, that in the event the date of the annual meeting is more than thirty (30) days before or more than sixty (60) days after such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the one hundred twentieth (120th) day prior to the date of such annual meeting and not later than the close of business on the later of: (A) the ninetieth (90th) day prior to the date of such annual meeting or, (B) if the first Public Announcement of the date of such annual meeting is less than one hundred (100) days prior to the date of such annual meeting, the tenth (10th) day following the day on which Public Announcement of the date of such annual meeting is first made by the Corporation; and
|
(ii)
|
Special Meeting Deadlines. In connection with the nomination of persons for election to the Board of Directors at a special meeting of stockholders (at which directors are to be elected or re-elected pursuant to the Corporation’s notice of meeting) in accordance with Section 2.3(b), not earlier than the close of business on the one-hundred twentieth (120th) day prior to such special meeting and not later than the close of business on the later of: (A) the ninetieth (90th) day prior to such special meeting, or (B) the tenth (10th) day following the day on which Public Announcement of the date of the special meeting is first made by the Corporation.
|
(b)
|
Notwithstanding anything in Section 2.8(a) to the contrary, if the number of persons to be elected to the Corporation’s Board of Directors is increased and there is no Public Announcement by the Corporation naming all of the nominees for director or specifying the size of the increased Board of Directors at least 100 days prior to the first anniversary of the preceding year’s annual meeting, a Noticing Stockholder’s notice required by these By-Laws shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it is delivered to the Secretary at the Corporation’s principal executive offices not later than the close of business on the tenth (10th) day following the day on which the Public Announcement naming all nominees or specifying the size of the increased Board of Directors is first made by the Corporation.
|
(c)
|
To be in proper form, whether in regard to nominating persons to be elected or re-elected to the Corporation’s Board of Directors or any other business, a Noticing Stockholder’s written notice required by these By-Laws must completely and accurately:
|
(i)
|
Set forth, as to each Noticing Stockholder and, if a Noticing Stockholder holds for the benefit of another, the beneficial owner on whose behalf the nomination or proposal is made (any Noticing Stockholder or such beneficial owner a “Holder” and, collectively, “Holders”), the following information together with a representation as to the completeness and accuracy of the information:
|
(A)
|
(i) the name and address of the Noticing Stockholder as they appear on the Corporation’s books and the residence address (if different from the Corporation’s books) of the Noticing Stockholder, (ii) if the Noticing Stockholder holds for the benefit of another, the name and
|
(B)
|
the class or series and number of shares of the Corporation that are, directly or indirectly, owned beneficially or of record by each Holder and each Holder Associated Person covered by this Section 2.8(c)(i), and the date such ownership was acquired;
|
(C)
|
a description of any Derivative Instrument that is directly or indirectly owned beneficially by any Holder or Holder Associated Person and any other direct or indirect opportunity to profit or share in any profit derived from any increase or decrease in the value of shares or other securities of the Corporation;
|
(D)
|
any proxy, contract, arrangement, understanding, or relationship pursuant to which any Holder or Holder Associated Person has a right to vote or has granted a right to vote any securities (including the shares of common stock) of the Corporation;
|
(E)
|
a description of any Hedging Transaction entered into by or on behalf of any Holder or Holder Associated Person;
|
(F)
|
any rights to dividends or other distributions on the shares or other securities of the Corporation owned beneficially by any Holder or Holder Associated Person that are separated or separable from the underlying shares or other securities of the Corporation;
|
(G)
|
any proportionate interest in shares or other securities of the Corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership or limited liability company or other entity in which any Holder or Holder Associated Person is a general partner or, directly or indirectly, beneficially owns an interest in a general partner, is the manager, managing member or directly or indirectly beneficially owns an interest in the manager or managing member of a limited liability company or similar entity;
|
(H)
|
any performance-related fees (other than an asset-based fee) that any Holder or Holder Associated Person is entitled to based on any increase or decrease in the value of shares or other securities of the Corporation or Derivative Instruments, if any;
|
(I)
|
a representation that the Noticing Stockholder intends to appear in person or by proxy at the meeting to nominate the persons named or
|
(J)
|
any other information relating to the Holder and any Holder Associated Person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal or for the election of directors in a contested election pursuant to Section 14 of the Exchange Act and the rules and regulations thereunder (even if an election contest or proxy solicitation is not involved), or is otherwise required pursuant to Section 14 of the Exchange Act.
|
(ii)
|
If a Noticing Stockholder’s notice required by these By-Laws relates to any business other than the nomination of one or more persons to be elected or re-elected to the Corporation’s Board of Directors that is proposed to be brought before the meeting, the notice also must set forth:
|
(A)
|
a brief description of the business desired to be brought before the meeting (including the specific text of any resolutions or actions proposed for consideration and if such business includes the proposal to amend the Corporation’s Certificate of Incorporation or By-Laws, the specific language of the proposed amendment) and the reasons for conducting such business at the meeting; and
|
(B)
|
a description of all direct and indirect agreements, arrangements or understandings between the Holder, any Holder Associated Person and any other Person (including their names) in connection with the proposal of such business by the Holder and any material direct or indirect interest of the Holder, any Holder Associated Person or any such other Person in such business.
|
(iii)
|
If a Noticing Stockholder’s notice required by these By-Laws relates to the nomination of a person (each such person a “Nominee” and collectively, “Nominees”) to be elected or re-elected to the Corporation’s Board of Directors, the written notice, as to each Nominee, also must:
|
(A)
|
set forth the Nominee’s name, age, business and residence address and principal occupation or employment and the class or series and
|
(B)
|
set forth a description (including party names) of any agreements, arrangements or understandings (including financial transactions) between or among the Holder, any Holder Associated Person or any Nominee, on the one hand, and any other Persons (including any Holder Associated Person and any Nominee), on the other hand, in connection with the Nominee’s nomination; and
|
(C)
|
set forth a description of all direct and indirect compensation and any other material monetary agreements, arrangements or understandings during the past three years, and any other material relationships, between or among the Holder, any Holder Associated Person and their respective Affiliates and Associates, or other Persons acting in concert therewith, on the one hand, and each Nominee, and his or her respective Affiliates and Associates, or other Persons acting in concert therewith, on the other hand.
|
(iv)
|
Any notice submitted pursuant to this Section 2.8(c) shall be updated and supplemented by the Holder in writing and delivered to the Secretary at the Corporation’s principal executive offices not later than 10 days after the record date for the meeting, if necessary, so that the information provided or required to be provided in such notice shall be true and correct as of the record date for the meeting.
|
(d)
|
In addition to the other terms that are defined in these By-Laws, for purposes of these By-Laws, the following terms shall have the respective meanings ascribed thereto:
|
(i)
|
“Affiliate” means a Person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, another specified Person.
|
(ii)
|
“Associate” means, with respect to a specified Person:
|
(A)
|
any corporation or organization of which that Person is an officer or partner or of which that Person is, directly or indirectly, the beneficial owner of ten percent (10%) or more of any class of equity securities;
|
(B)
|
any trust or other estate in which that Person has a substantial beneficial interest or as to which such Person serves as trustee or in a similar fiduciary capacity; or
|
(C)
|
any Immediate Family Member of that Person.
|
(iii)
|
“Control” means the possession, direct or indirect, of the power to direct or cause the direction of the management policies of a person, whether through the ownership of voting securities, by contract, or otherwise.
|
(iv)
|
“Derivative Instrument” means any derivative positions including, without limitation, any option, warrant, convertible security, stock appreciation right, profits interest or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares or other securities of the Corporation or with a value derived in whole or in part from the value of any class or series of shares or other securities of the Corporation, whether or not the instrument or right shall be subject to settlement in the underlying class or series of shares or other securities of the Corporation or otherwise and any performance-related fees to which such Holder or Holder Associated Person is entitled based, directly or indirectly, on any increase or decrease in the value of shares or other securities of the Corporation.
|
(v)
|
“Hedging Transaction” means, any hedging or other transaction (such as borrowed or loaned shares) or series of transactions, or any other agreement, arrangement or understanding, the effect or intent of which is to increase or decrease the voting power or economic or pecuniary interest of a Holder or Holder Associated Person with respect to the Corporation’s securities, including, without limitation, a short interest in any securities (including the shares of common stock) of the Corporation (for purposes of these By-Laws a person shall be deemed to have a short interest in a security if a Holder or Holder Associated Person directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has the opportunity to profit or share in any profit derived from any decrease in the value or price of the subject security).
|
(vi)
|
“Holder Associated Person” means, with respect to any Holder, (A) any person acting in concert with such Holder, (B) any beneficial owner of shares of stock of the Corporation owned of record or beneficially by such Holder (other than a stockholder that is a depositary) and (C) any Person, directly or indirectly, controlling, controlled by or under common control with any Holder, or any Holder Associated Person identified in clauses (A) or (B) above.
|
(vii)
|
“Immediate Family Member” means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of a specified person, and any person (other than a tenant or employee) sharing the household of such specified person.
|
(viii)
|
“Person” means an individual, partnership, corporation (including a business trust), limited liability company, joint stock company, trust, unincorporated association, joint venture or other entity, or a government or any political subdivision or agency thereof.
|
(ix)
|
“Public Announcement” means disclosure by the Corporation in a press release reported by the Dow Jones News Service, Associated Press, Business Wire, PR Newswire or comparable national news service or in a document publicly filed with or furnished by the Corporation to the Securities and Exchange Commission pursuant to Section 13, 14, or 15(d) of the Exchange Act and the rules and regulations thereunder.
|
(e)
|
Only those persons who are nominated in accordance with the procedures set forth in these By-Laws shall be eligible to serve as directors. Only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in these By-Laws. Except as otherwise provided by law, the Certificate of Incorporation, or these By-Laws, the Chairman of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made or proposed, as the case may be, in compliance with the procedures set forth in these By-Laws and, if any nomination or proposed business is not in compliance with these By-Laws, to declare that such nomination or proposed business is defective, in which case it shall be disregarded.
|
(f)
|
In addition to the foregoing provisions of these By-Laws, a Holder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in these By-Laws; provided, however, that any references in these By-Laws to the Exchange Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to
|
(g)
|
Nothing in these By-Laws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the Exchange Act. In addition, nothing in these By-Laws shall be deemed to affect any rights of the holders of any series of Preferred Stock to elect directors under specified circumstances.
|
(a)
|
The interest of each stockholder of the Corporation shall be evidenced by certificates for shares of stock in such form as the appropriate officers of the Corporation may from time to time prescribe; provided that the Board of Directors may provide by
|
(b)
|
The shares of stock represented by certificates shall be signed, countersigned and registered in such manner as the Board of Directors may by resolution prescribe, which resolutions may permit all or any of the signatures on such certificates (if any) to be by facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar at the date of issue.
|
(c)
|
The shares of the stock of the Corporation represented by certificates shall be transferred on the books of the Corporation by the holder thereof in person or by his attorney, upon surrender for cancellation of certificates for at least the same number of shares, with an assignment and power of transfer endorsed thereon or attached thereto, duly executed, with such proof of the authenticity of the signature as the Corporation or its agents may reasonably require. Upon receipt of proper transfer instructions from the registered owner of uncertificated shares, such uncertificated shares shall be canceled and issuance of new equivalent uncertificated shares or certificated shares (if authorized) shall be made to the person entitled thereto and the transaction shall be recorded upon the books of the Corporation.
|
(d)
|
Within a reasonable time after the issuance or transfer of uncertificated shares, the Corporation shall send to the registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to the General Corporation Law of the State of Delaware or, unless otherwise provided by the General Corporation Law of the State of Delaware, a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.
|
(a)
|
Each person who was or is made a party or is threatened to be made a party to or is involved in any action, suit, or proceeding, whether civil, criminal, administrative or investigative (hereinafter a “proceeding”), by reason of the fact that such person
|
(b)
|
To obtain indemnification under this By-Law, a claimant shall submit to the Corporation a written request, including therein or therewith such documentation and information as is reasonably available to the claimant and is reasonably necessary to determine whether and to what extent the claimant is entitled to indemnification. Upon written request by a claimant for indemnification pursuant to the first sentence of this paragraph (b), a determination, if required by applicable law, with respect to
|
(c)
|
If a claim under paragraph (a) of this By-Law is not paid in full by the Corporation within 30 days after a written claim pursuant to paragraph (b) of this By-Law has been received by the Corporation, the claimant may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and, if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where the required undertaking, if any is required, has been tendered to the Corporation) that the claimant has not met the standard of conduct which makes it permissible under the General Corporation Law of the State of Delaware for the Corporation to indemnify the claimant for the amount claimed, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its Board of Directors, Independent Counselor stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because such claimant has met the applicable standard of conduct set forth in the General Corporation Law of the State of Delaware, nor an actual determination by the Corporation (including its Board of Directors, Independent Counsel or stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.
|
(d)
|
If a determination shall have been made pursuant to paragraph (b) of this By-Law that the claimant is entitled to indemnification, the Corporation shall be bound by such determination in any judicial proceeding commenced pursuant to paragraph (c) of this By-Law.
|
(e)
|
The Corporation shall be precluded from asserting in any judicial proceeding commenced pursuant to paragraph (C) of this By-Law that the procedures and presumptions of this By-Law are not valid, binding and enforceable and shall stipulate in such proceeding that the Corporation is bound by all the provisions of this By-Law.
|
(f)
|
The right to indemnification and the payment of expenses incurred in defending a proceeding in advance of its final disposition conferred in this By-Law shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, By-Laws, agreement, vote of stockholders or Disinterested Directors or otherwise. No repeal or modification of this By-Law shall in anyway diminish or adversely affect the rights of any director, officer, employee or agent of the Corporation hereunder in respect of any occurrence or matter arising prior to any such repeal or modification.
|
(g)
|
The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the General Corporation Law of the State of Delaware. To the extent that the Corporation maintains any policy or policies providing such insurance, each such director or officer, and each such agent or employee to which rights to indemnification have been granted as provided in paragraph (h) of this By-Law, shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage thereunder for any such director, officer, employee or agent.
|
(h)
|
The Corporation may, to the extent authorized from time to time by the Board of Directors, grant rights to indemnification, and rights to be paid by the Corporation the expenses incurred in defending any proceeding in advance of its final disposition, to any employee or agent of the Corporation to the fullest extent of the provisions of this By-Law with respect to the indemnification and advancement of expenses of directors and officers of the Corporation.
|
(i)
|
If any provision or provisions of this By-Law shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (1) the validity, legality and enforceability of the remaining provisions of this By-Law (including, without limitation, each portion of any paragraph of this By-Law containing any such provision held to be invalid, illegal or unenforceable, that is not itself held to be invalid, illegal or unenforceable) shall not in anyway be affected or impaired thereby; and (2) to the fullest extent possible, the provisions of this By-Law (including, without limitation, each such portion of any paragraph of this By-Law containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.
|
(j)
|
For purposes of this By-Law:
|
(i)
|
“Disinterested Director” means a director of the Corporation who is not and was not a party to the matter in respect of which indemnification is sought by the claimant.
|
(ii)
|
“Independent Counsel” means a law firm, a member of a law firm, or an independent practitioner, that is experienced in matters of corporation law and shall include any person who, under the applicable standards of professional conduct then prevailing, would not have a conflict of interest in representing either the Corporation or the claimant in an action to determine the claimant’s rights under this By-Law.
|
(k)
|
Any notice, request or other communication required or permitted to be given to the Corporation under this By-Law shall be in writing and either delivered in person or sent by telecopy, telex, telegram, overnight mail or courier service, or certified or registered mail, postage prepaid, return receipt requested, to the Secretary of the Corporation and shall be effective only upon receipt by the Secretary.
|
•
|
Examine, without charge, at the Plan Administrator's office and at other specified locations, such as worksites, all documents governing the Plan, including a copy of the latest annual report (Form 5500 Series) filed by the Plan with the U.S. Department of Labor.
|
•
|
Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the Plan, including a copy of the latest annual report (Form 5500 Series) and updated summary plan description. The Administrator may make a reasonable charge for the copies.
|
•
|
Receive a summary of the Plan's annual financial report. The Plan Administrator is required by law to furnish each participant with a copy of this summary annual report.
|
|
/S/ Paul B. Kusserow
|
Paul B. Kusserow
|
President and Chief Executive Officer
(Principal Executive Officer)
|
|
/S/ Scott G. Ginn
|
Scott G. Ginn
Chief Financial Officer
|
(Principal Financial Officer)
|
|
/S/ Paul B. Kusserow
|
Paul B. Kusserow
President and Chief Executive Officer
|
(Principal Executive Officer)
|
|
/S/ Scott G. Ginn
|
Scott G. Ginn
Chief Financial Officer
|
(Principal Financial Officer)
|